What is Mabwell (Shanghai) Bioscience Co., Ltd.'s (688062.SS) StockRank?

MoatMap's StockRank for Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) is 3/100, with a Strong Sell signal. This is a composite score combining Quality (15), Value (33), and Momentum (29) factor ranks across MoatMap's 20,000+ stock universe.

Does Mabwell (Shanghai) Bioscience Co., Ltd. have an economic moat?

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) has a Quality factor score of 15/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Mabwell (Shanghai) Bioscience Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) is Strong Sell, based on a StockRank of 3/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Mabwell (Shanghai) Bioscience Co., Ltd. in?

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688062.SS

STRONG SELLREMOVE

Mabwell (Shanghai) Bioscience Co., Ltd. · Healthcare · China · $2.0B · Avg Vol: $36M/d

StockRank

P/E (TTM)

—

ROE

-118.9%

D/E

11.3x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

$7.4M · 1d →

AI CONVICTION THESIS

A biotechnology developer with high R&D expenses and no proprietary CDMO platform, making it a consumer of capital rather than a CDMO beneficiary.

COMPANY DESCRIPTION

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical company focused on the discovery and development of therapeutic antibodies, ADC drugs, and biosimilars. The company possesses a fully integrated R&D platform spanning target validation, antibody engineering, and commercial-scale manufacturing. It is a clinical-stage biotechnology innovator with a diversified pipeline targeting oncology, autoimmune, and ophthalmic diseases.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	4M	19M	30M	98M	188.0%
EPS	-0.36	-0.39	-0.39	-0.36	—
Shares	400M	400M	400M	400M	0.0%
Debt	114M	191M	328M	432M	55.6%
Equity	520M	382M	232M	52M	-53.7%
Op CF	-106M	-116M	-141M	-43M	—
Inv CF	-89M	-75M	-43M	-29M	—
Fin CF	549M	66M	123M	117M	—

PRICE (1M)-21.8%

SMA 50SMA 200

$4.06

RSI (14)

34.0

52W High

$9.40

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-37.7%18.2

ROE

-118.9%6.5

GP/Assets

14.3%33.8

Op. Margin

-160.5%14.9

FCF/Assets

-7.5%31.5

Piotroski

—7.2

Int. Cover

-9.5x25.1

D/E Ratio

11.29x0.7

Current Ratio

0.88x7.2

Value

P/E (TTM)

—N/A

EV/EBITDA

-21.2x87.2

P/FCF

—N/A

P/B

103.1x0.7

P/S

16.6x19.0

Div Yield

—N/A

Momentum

52W High %

43%16.0

RS 6M

-45%26.4

SMA 50/200

0.84x20.6

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+81%66.3

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$2.0B

P/E (Forward)

-64.2x

Gross Margin

87.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688062.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
688062.SS	Mabwell (Shanghai) Bioscience Co., Ltd.(you)	$2.0B	3	STRONG SELL
6855.HK	Ascentage Pharma Group International	$1.9B	4	STRONG SELL
2617.HK	TransThera Sciences (Nanjing), Inc.	$1.8B	4	STRONG SELL
AAPG	Ascentage Pharma Group Internat	$1.9B	1	STRONG SELL
7666.HK	METIS TECHBIO-P	$2.2B	7	STRONG SELL
6872.HK	TENNOR THERAP-B	$1.4B	2	STRONG SELL
688520.SS	Sinocelltech Group Limited	$2.7B	8	STRONG SELL
6938.HK	Suzhou Ribo Life Science Co	$1.3B	5	STRONG SELL
688382.SS	InventisBio Co., Limited	$1.7B	12	STRONG SELL
688177.SS	Bio-Thera Solutions, Ltd.	$1.2B	5	STRONG SELL

Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.0%

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) — Stock Score Summary

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) has a MoatMap StockRank of 3/100 based on Quality (15/100), Value (33/100), and Momentum (29/100) factor scores. The current signal is STRONG SELL. A biotechnology developer with high R&D expenses and no proprietary CDMO platform, making it a consumer of capital rather than a CDMO beneficiary.

Key Financial Metrics

Price	$4.06
Market Cap	$2.0B
P/E (Forward)	-64.23
Price/Book	103.06
Return on Equity	-118.9%
Return on Invested Capital	-37.7%
Debt/Equity	1129.09
Gross Margin	87.1%
Operating Margin	-160.5%
Revenue Growth	184.9%
Free Cash Flow	$-7M

Mabwell (Shanghai) Bioscience Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Mabwell (Shanghai) Bioscience Co., Ltd.’s (688062.SS) StockRank?: MoatMap’s StockRank for Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) is 3/100, with a Strong Sell signal. It is a composite of Quality (15), Value (33), and Momentum (29) factor ranks across MoatMap’s 20,000+ stock universe.
Does Mabwell (Shanghai) Bioscience Co., Ltd. have an economic moat?: Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) has a Quality factor score of 15/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Mabwell (Shanghai) Bioscience Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) is Strong Sell, based on a StockRank of 3/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Mabwell (Shanghai) Bioscience Co., Ltd. in?: Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).